Hypofractionated radiosurgery for localized prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a short course of high-dose radiation therapy (radiosurgery) for prostate cancer that hasn't spread. It aims to treat the cancer with fewer sessions while keeping side effects low.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that hasn't spread beyond the prostate (stages T1 to T2c).
- Your Gleason score is 7 or lower (grade group 1, 2, or 3).
- You are 18 years or older.
- Your PSA level is less than 20 ng/ml.
- Your prostate volume is less than 80 cm³ (about the size of a small apple).
- You have mild or no urinary symptoms (IPSS score of 12 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests radiation therapy for men with very high-risk prostate cancer that hasn't spread. It aims to see if targeting the tumor with radiation can help control the cancer in this highest risk group.
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) for men who have already had their prostate removed and still have signs of cancer (like rising PSA). The goal is to see if this can help prevent the cancer from coming back.
This Phase 3 trial tests whether giving a smaller amount of radiation (“hypo-fractionated” means fewer, larger sessions) can work as well as standard approaches for intermediate-risk prostate cancer. It also compares adding hormone therapy (“androgen suppression”) to radiation versus using radiation alone.
This trial studies a more sped-up radiation schedule for men with certain local prostate cancers, given together with hormone therapy. It aims to keep cancer control while possibly reducing treatment time and making care easier.
This trial tests a shorter course of radiation therapy (hypofractionated whole-pelvis radiation) combined with a high-dose-rate (HDR) brachytherapy boost for men with high-risk or unfavorable intermediate-risk prostate cancer. The goal is to see if this approach controls cancer while possibly reducing side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.